| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865690 | SUN PHARM | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2024
(2 months from now) | |
| US9211295 | SUN PHARM | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2024
(2 months from now) | |
| US8143240 | SUN PHARM | 17α, 21-dihydroxypregnene esters as antiandrogenic agents |
Jan, 2025
(8 months from now) | |
| US9486458 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(4 years from now) | |
| US10159682 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Aug, 2028
(4 years from now) | |
| US11207332 | SUN PHARM | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Nov, 2028
(4 years from now) | |
| US9433628 | SUN PHARM | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Feb, 2029
(4 years from now) | |
| US8785427 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2030
(6 years from now) | |
Winlevi is owned by Sun Pharm.
Winlevi contains Clascoterone.
Winlevi has a total of 8 drug patents out of which 0 drug patents have expired.
Winlevi was authorised for market use on 26 August, 2020.
Winlevi is available in cream;topical dosage forms.
Winlevi can be used as method of treating acne vulgaris with topically applied cortexolone 17a-propionate, method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate.
Drug patent challenges can be filed against Winlevi from 26 August, 2024.
The generics of Winlevi are possible to be released after 25 July, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate
Dosage: CREAM;TOPICAL
WINLEVI family patents
